Biosimilars Council Encourages Stakeholders, Advocates to Join #GlobalBiosimilarsWeek

WASHINGTON, D.C. (November 1, 2021) – AAM’s Biosimilars Council, in accordance with the International Generic and Biosimilar Medicines Association (IGBA), invites all biosimilars advocates and stakeholders to take part in the second annual Global Biosimilars Week on November 1st–5th. This social media awareness campaign will gather biosimilar resources, ideas, and stories from around the world under the hashtag #GlobalBiosimilarsWeek.

The growing use of biosimilar medicines is revolutionizing global health, as they help more patients treat serious chronic illnesses at a fraction of the cost of brand name biologics. However, many people still lack awareness of biosimilars and the incredible benefits they provide. Global Biosimilars Week is meant to bridge that awareness gap, said Biosimilars Council Executive Director Christine Simmon. The Biosimilars Council has been proud to organize this event and engage with our counterparts around the world. By sharing our unique resources and stories, we will present a unified voice for biosimilars that will extend well beyond this week and ultimately achieve our shared goal of advancing biosimilar access for all.

The COVID-19 global health crisis has led governments and the entire healthcare community to rethink and rebuild healthcare systems. This includes focusing on their ability to efficiently deliver access to biologic therapies and to effectively address Non-Communicable Diseases (NCDs), explained Sudarshan Jain, Chair of the IGBA. Now is a time to reconcile the unique opportunity provided by the availability of biosimilar medicines and the rising challenges for many patients around the world to access quality-assured transformative therapies. We need to redouble the efforts to effectively tackle NCDs and biosimilar medicines are part of the solution.

With 15 years of positive biosimilar medicines contribution to patient health and healthcare system sustainability, the challenges and remedies to efficient use of biosimilar medicines are well known. Our new white paper aims to facilitate experience sharing for communities wanting to Advance Access in their country or region and more importantly to implement effective and tailored strategies in tackling Non-Communicable Diseases locally, said Julie Maréchal-Jamil, Co-Chair of the IGBA Biosimilars Committee.

Additionally, on November 2nd, IGBA will host an online webinar Unlocking the Global Biosimilar Opportunity in Tackling Non-Communicable Diseases to provide valuable information and expert insights.


Rachel Schwartz


About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.